Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol

European Archives of Psychiatry and Clinical Neuroscience

Volumn 263, Issue 1, 2013, Pages 65-74

  Giegling, Ina ^a   Balzarro, Beatrice ^b   Porcelli, Stefano ^b   Schäfer, Martin ^a,c   Hartmann, Annette M ^a   Friedl, Marion ^a   Konte, Bettina ^a   Krämer, Philipp ^a   Möller, Hans Jürgen ^a   De Ronchi, Diana ^b   Stassen, Hans H ^d   Serretti, Alessandro ^b   Rujescu, Dan ^a,e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c KLINIKEN ESSEN MITTE   (Germany)

^d UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Antipsychotics; Gene; Haloperidol; Pharmacogenetics; Schizophrenia

Indexed keywords

ANKYRIN; ANKYRIN REPEAT AND KINASE DOMAIN CONTAINING 1 PROTEIN; DOPAMINE 2 RECEPTOR; HALOPERIDOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CATATONIC SCHIZOPHRENIA; DELUSION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; HAPLOTYPE; HEBEPHRENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PARANOID SCHIZOPHRENIA; PHARMACOGENETICS; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DNA MUTATIONAL ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HALOPERIDOL; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873312715     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-012-0348-1     Document Type: Article

References (48)

1. Tandon R, Keshavan MS, Nasrallah HA (2008) Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 102(1-3):1-18
2. Lennertz L, Quednow BB, Benninghoff J, Wagner M, Maier W, Mossner R (2011) Impact of TCF4 on the genetics of schizophrenia. Eur Arch Psychiatry Clin Neurosci 261(Suppl 2):S161-S165
3. Arranz MJ, Rivera M, Munro JC (2010) Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 25(11):933-969
4. Crisafulli C, Chiesa A, Han C, Lee SJ, Park MH, Balzarro B, Andrisano C, Patkar AA, Pae CU, Serretti A (2011) Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. Eur Arch Psychiatry Clin Neurosci 262(3):199-205
5. Mossner R, Schuhmacher A, Wagner M, Lennertz L, Steinbrecher A, Quednow BB, Rujescu D, Rietschel M, Maier W (2011) The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms. Eur Arch Psychiatry Clin Neurosci 262(3):193-197
6. Tiwari AK, Zai CC, Muller DJ, Kennedy JL (2010) Genetics in schizophrenia: where are we and what next? Dialogues Clin Neurosci 12(3):289-303
7. Arinami T, Gao M, Hamaguchi H, Toru M (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6(4):577-582 (Pubitemid 27142107)
8. Jonsson EG, Nothen MM, Neidt H, Forslund K, Rylander G, Mattila-Evenden M, Asberg M, Propping P, Sedvall GC (1999) Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizophr Res 40(1):31-36 (Pubitemid 29459005)
9. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L (2005) Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 376(1):1-4
10. Malhotra AK (2004) Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain. Neurotox Res 6(1):51-56
11. Tanaka T, Igarashi S, Onodera O, Tanaka H, Fukushima N, Takahashi M, Kameda K, Tsuji S, Ihda S (1996) Lack of association between dopamine D2 receptor gene Cys311 variant and schizophrenia. Am J Med Genet 67(2):208-211
12. Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH (2004) Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol (CINP) 7(4):461-470
13. Shaikh S, Collier D, Arranz M, Ball D, Gill M, Kerwin R (1994) DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet 343(8904):1045-1046
14. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12(3):205-216 (Pubitemid 36204418)
15. Hirvonen J, Aalto S, Lumme V, Nagren K, Kajander J, Vilkman H, Hagelberg N, Oikonen V, Hietala J (2003) Measurement of striatal and thalamic dopamine D2 receptor binding with 11Craclopride. Nucl Med Commun 24(12):1207-1214 (Pubitemid 39619582)
16. Lawford BR, Young RM, Swagell CD, Barnes M, Burton SC, Ward WK, Heslop KR, Shadforth S, van Daal A, Morris CP (2005) The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia. Schizophr Res 73(1):31-37 (Pubitemid 39574676)
17. Monakhov M, Golimbet V, Abramova L, Kaleda V, Karpov V (2008) Association study of three polymorphisms in the dopamine D2 receptor gene and schizophrenia in the Russian population. Schizophr Res 100(1-3):302-307
18. Ponce G, Perez-Gonzalez R, Aragues M, Palomo T, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J (2009) The ANKK1 kinase gene and psychiatric disorders. Neurotox Res 16(1):50-59
19. Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Otani K, Furukori H, Kaneko S, Inoue Y (2001) Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report. Eur Arch Psychiatry Clin Neurosci 251(2):57-59 (Pubitemid 32488032)
20. Noble EP (2003) D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 116B(1):103-125 (Pubitemid 37063624)
21. Pohjalainen T, Rinne JO, Nagren K, Syvalahti E, Hietala J (1998) Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 155(6):768-773 (Pubitemid 28252655)
22. Thompson TL, Moss RL (1997) Modulation of mesolimbic dopaminergic activity over the rat estrous cycle. Neurosci Lett 229(3):145-148 (Pubitemid 27316067)
23. Schafer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, Moller HJ (2001) Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 158(5):802-804 (Pubitemid 32429852)
24. Shen YC, Chen SF, Chen CH, Lin CC, Chen SJ, Chen YJ, Luu SU (2009) Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 43(6):600-606
25. Suzuki A, Kondo T, Mihara K, Furukori H, Nagashima U, Ono S, Otani K, Kaneko S (2000) Association between Taq1 a dopamine D2 receptor polymorphism and psychopathology of schizophrenia in Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry 24(7):1105-1113 (Pubitemid 32268866)
26. Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N (2003) Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J 3(6):356-361 (Pubitemid 38072174)
27. Neville MJ, Johnstone EC, Walton RT (2004) Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23(6):540-545 (Pubitemid 38720604)
28. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29(1):15-31 (Pubitemid 36871054)
29. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261-276 (Pubitemid 18039085)
30. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 334:1-100 (Pubitemid 17115352)
31. Chen L, Ascher-Svanum H, Stauffer V, Kinon BJ, Kollack-Walker S, Ruberg S (2009) Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr Res 113(1):34-40
32. Obermeier M, Schennach-Wolff R, Meyer S, Moller HJ, Riedel M, Krause D, Seemuller F (2011) Is the PANSS used correctly? A systematic review. BMC Psychiatry 11:113
33. Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G (2005) Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res 77(2-3):119-128 (Pubitemid 41112206)
34. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676 (Pubitemid 19154942)
35. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19
36. Oeth P, del Mistro G, Marnellos G, Shi T, van den Boom D (2009) Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY). Methods Mol Biol (Clifton, NJ) 578:307-343
37. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, Swan GE, Rutter J, Bertelsen S, Fox L, Fugman D, Goate AM, Hinrichs AL, Konvicka K, Martin NG, Montgomery GW, Saccone NL, Saccone SF, Wang JC, Chase GA, Rice JP, Ballinger DG (2007) Novel genes identified in a highdensity genome wide association study for nicotine dependence. Hum Mol Genet 16(1):24-35 (Pubitemid 46152542)
38. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL (2008) Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 13(6):570-584 (Pubitemid 351704941)
39. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125(1-2):279-284 (Pubitemid 33000466)
40. Barrett JC (2009) Haploview: visualization and analysis of SNP genotype data. Cold Spring Harbor protocols 2009 (10): pdb ip71
41. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D,Maller J, Sklar P, deBakker PI, DalyMJ, ShamPC(2007) PLINK: a tool set for whole-genome association and populationbased linkage analyses. Am J Hum Genet 81(3):559-575 (Pubitemid 47330214)
42. Dubertret C, Bardel C, Ramoz N, Martin PM, Deybach JC, Ades J, Gorwood P, Gouya L (2010) A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes. Prog Neuropsychopharmacol Biol Psychiatry 34(3):492-499
43. Houston J, Dharia S, Bishop JR, Ellingrod VL, Fijal B, Jacobson JG, Hoffmann VP (2011) Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Res 187(1-2):74-79
44. Bakker PR, Bakker E, Amin N, van Duijn CM, van Os J, van Harten PN (2012) Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One 7(5):e36561
45. Lencz T, Robinson DG, Napolitano B, Sevy S, Kane JM, Goldman D, Malhotra AK (2010) DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics 20(9):569-572
46. Cordeiro Q, Siqueira-Roberto J, Zung S, Vallada H (2009) Association between the DRD2-141C insertion/deletion polymorphism and schizophrenia. Arq Neuropsiquiatr 67(2A):191-194
47. Parsons MJ, Mata I, Beperet M, Iribarren-Iriso F, Arroyo B, Sainz R, Arranz MJ, Kerwin R (2007) A dopamine D2 receptor generelated polymorphism is associated with schizophrenia in a Spanish population isolate. Psychiatr Genet 17(3):159-163 (Pubitemid 46716208)
48. Sullivan PF (2007) Spurious genetic associations. Biol Psychiatry 61(10):1121-1126 (Pubitemid 46669468)